Mandate

Vinge advises Cellink in conjunction with the acquisition of Scienion Ag

Vinge has advised Cellink AB, listed on Nasdaq Stockholm, in connection with the acquisition of all shares in Scienion Ag. Scienion is a life science company which focuses on precision dimensioning technology.

The Scienion group conducts operations in Germany, the United States, France and England. The purchase price for the shares, on a cash‑free and debt‑free basis, amounts to EUR 80 million, of which EUR 40 million is paid in cash and the remaining EUR 40 million is paid in newly issued Cellink shares. Closing is expected to take place at the end of August whereupon Cellink’s board of directors will adopt a resolution concerning the issue in kind in accordance with the authorization resolved at the company’s general meeting. Cellink intends to perform a new issue of shares in order to finance the cash element of the purchase price.

Vinge’s team has consisted of, among others, Anders StridMartin E Svanberg (M&A), Edin Agic (Capital Markets) as well as Anna Palmérus (Competition Law). Hengeler Mueller advised Cellink in Germany.

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025